← Candel Therapeutics, Inc. (CADL) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Candel Therapeutics, Inc. (CADL)
Biological Products, (No Diagnostic Substances) · market cap $899M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-12 (est.)
Earnings
Pipeline
4
programs
Upcoming events
4
next 90d+
Dossier
Ready
cached
Candel Therapeutics (CADL) is a clinical-stage oncolytic viral immunotherapy company with 38 employees and a $701M market cap. Its lead asset, aglatimagene besadenovec (CAN-2409), is in Phase 3 trials for localized prostate cancer, both as monotherapy and in combination with valacyclovir. A near-term Phase 2 data readout for the combination is expected around August 15, 2026, making it the primary binary catalyst in the near term.
The catalyst path
- 2026-11-12 (est.)Earningsimp 5/10
- 2026-12-31NDA Filingimp 5/10
- 2027-02-15 (est.)Phase 2 · aglatimagene besadenovec + valacyclovirimp 7/10
- 2027-08-07 (est.)PDUFA · aglatimagene besadenovecimp 8/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| aglatimagene besadenovec | Phase 3 | Prostate Cancer |
| CAN-2409 | Phase 2 | Malignant Glioma |
| Valacyclovir | Phase 3 | Non-squamous, Non-Small Cell Lung Cancer |
| aglatimagene besadenovec + valacyclovir | Phase 3 | Prostate Cancer Patients Treated by Radiotherapy |
Price & technical context
3-month
+2.2%
6-month
+105.0%
12-month
+85.0%
52-wk range
$4.42–$13.75
vs 50-day MA
-10.4%
vs 200-day MA
+28.7%
Realized vol
70.7%
Max drawdown
-64.0%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CADL (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.